Barclays Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price boosted by research analysts at Barclays from $60.00 to $62.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s target price points to a potential upside of 27.10% from the company’s current price.

TARS has been the subject of a number of other research reports. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Oppenheimer raised their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $56.00.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $48.78 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market cap of $1.86 billion, a PE ratio of -12.80 and a beta of 1.02. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.14. The stock has a fifty day moving average price of $51.04 and a 200 day moving average price of $39.10.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after acquiring an additional 420,057 shares during the last quarter. Millennium Management LLC grew its holdings in Tarsus Pharmaceuticals by 1,259.3% in the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after purchasing an additional 322,942 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Tarsus Pharmaceuticals in the third quarter valued at approximately $10,587,000. Finally, Ikarian Capital LLC increased its position in Tarsus Pharmaceuticals by 28.7% during the third quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after purchasing an additional 230,000 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.